Acetazolamide Therapy in Patients with Heart Failure: A Meta-Analysis
Aeddula, Narothama Reddy
Mao, Michael A
AffiliationUniv Arizona, Dept Internal Med
MetadataShow full item record
CitationWongboonsin J, Thongprayoon C, Bathini T, Ungprasert P, Aeddula NR, Mao MA, Cheungpasitporn W. Acetazolamide Therapy in Patients with Heart Failure: A Meta-Analysis. Journal of Clinical Medicine. 2019; 8(3):349.
JournalJOURNAL OF CLINICAL MEDICINE
Rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractNine studies (three randomized controlled trials and six cohort studies) with a total of 229 HF patients were enrolled. After acetazolamide treatment, there were significant decreases in serum pH (mean difference (MD) of -0.04 (95% CI, -0.06 to -0.02)), pCO₂ (MD of -2.06 mmHg (95% CI, -3.60 to -0.53 mmHg)), and serum bicarbonate levels (MD of -6.42 mmol/L (95% CI, -10.05 to -2.79 mmol/L)). When compared to a placebo, acetazolamide significantly increased natriuresis (standardized mean difference (SMD) of 0.67 (95% CI, 0.08 to 1.27)), and decreased the apnea-hypopnea index (AHI) (SMD of -1.06 (95% CI, -1.75 to -0.36)) and central apnea index (CAI) (SMD of -1.10 (95% CI, -1.80 to -0.40)). Egger's regression asymmetry tests revealed no publication bias with p = 0.20, 0.75 and 0.59 for analysis of the changes in pH, pCO₂, and serum bicarbonate levels with use of acetazolamide in HF patients.
NoteOpen access journal
VersionFinal published version